Dr. Anusha Kalbasi is a physician-scientist and radiation oncologist in the UCLA Department of Radiation Oncology and UCLA Jonsson Comprehensive Cancer Center. Dr. Kalbasi specializes in the treatment of sarcoma and melanoma. Dr. Kalbasi combines laboratory research with clinical trials to develop new ways to overcome resistance to immunotherapy. As a radiation oncologist, he is experienced in advanced approaches, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), image-guided radiotherapy, and proton therapy.
Dr. Kalbasi earned his undergraduate and medical degrees with honors from UCLA and the David Geffen School of Medicine at UCLA, respectively, during which time he completed an HHMI-NIH research fellowship at the National Cancer Institute under Dr. Steven Rosenberg. He completed residency training in radiation oncology at the University of Pennsylvania, where he also completed a post-doctoral fellowship in tumor immunology under Dr. Gregory Beatty. He then completed a second post-doctoral fellowship in the laboratory of Dr. Antoni Ribas at UCLA, where he continued as a faculty member.
Dr. Kalbasi's research has been funded by the Conquer Cancer Foundation of ASCO, Radiological Society of North America, Tower Cancer Research Foundation, Sarcoma Foundation for America, Sarcoma Alliance through Research Collaboration, the Melanoma Research Alliance, the Damon Runyon Cancer Research Foundation, the UCLA CTSI KL2 Program and the National Institutes of Health (NCI).
Medical Board Certification
Areas of Focus
Dr. Kalbasi leads an NIH-funded research effort that involves laboratory research and clinical trials, focused on overcoming resistance to immunotherapy, especially with respect to treatment of sarcoma and melanoma.
- Grasso CS, Tsoi J, Onyschchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Shailender B, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen J, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. "Conserved interferon-gamma signaling and decreased immune exclusion programs in responses to immune checkpoint blockade therapy." Cancer Cell. 2020. Accepted.
- Graham DS, Onyshchenko M, Eckardt MA, DiPardo BJ, Venigalla S, Nelson SD, Chmielowski B, Singh AS, Shabason JE, Eilber FC, *Kalbasi A. "Chemotherapy Utilization and Timing in Primary Localized High-Grade Soft Tissue Sarcoma: Patterns of Care in the National Cancer Database." Journal of National Comprehensive Cancer Network. 2020. Accepted.
- Kalbasi A, Kamrava M, Chu F, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry SM, Hernandez JM, Chmielowski B, Singh AS, Bukata SV, Bernthal NM, Steinberg MS, Weidhaas JB, Eilber FC. "5-day neoadjuvant radiation therapy for high-risk primary soft tissue sarcoma: a phase II study." Clinical Cancer Research. 2020 Apr 15;26(8):1829-1836. doi: 10.1158/1078-0432.CCR-19-3524. Epub 2020 Feb 13.
- Kalbasi A, Ribas A. "Tumour-intrinsic resistance to immune checkpoint blockade." Nature Reviews Immunology. 2020 Jan;20(1):25-39.
- Schaefer IM, Kelvin Hong K, Kalbasi A. "How technology is improving the multidisciplinary care of sarcoma. Am Soc Clin Oncol Educ Book." 2020;40:445-462.
- Kalbasi A, Komar C, Tooker GM, Liu M, Gladney WL, Lee JW, Ben-Josef E, Beatty GL. "Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma." Clinical Cancer Research. 2017 Jan 1;23(1):137-148.
- Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Small D, Mitra N, Bekelman JE. "Relation of Dose-Escalated Radiation to Overall Survival in Men with Non-metastatic Prostate Cancer." JAMA Oncology. 2015 Oct; 1(7):897-906.
- Kalbasi A, June CH, Haas NB, Vapiwala N. "Radiation and Immunotherapy: A Nexus." Journal of Clinical Investigation. Review. 2013; 123(7):2756-2763.
- Kalbasi A, Shrimali R, Chinnasamy D, Rosenberg SA. "Prevention of apoptosis due to IL-2 withdrawal in lymphocytes retrovirally cotransduced with genes encoding an anti-tumor T cell receptor and an anti-apoptotic gene." Journal of Immunotherapy. 2010 Sep;33(7):672-83.
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)
- Super Doctors® Southern California Rising Stars 2021
- 2020 Damon Runyon Clinical Investigator Award
- 2020 NIH/NCI K08 Career Development Award
- Super Doctors® Southern California Rising Stars 2020
- 2018 SARC Career Development Award
- 2018 Society for Immunotherapy of Cancer Young Investigator Award
- 2018 UCLA CTSI KL2 Awardee
- 2018 Sarcoma Foundation of America Award
- 2017 RSNA Research Scholar
- 2017 Tower Cancer Research Foundation Young Investigator Award
- 2016 Fellow, ECCO-AACR-EORTC-ESMO Methods in Clinical Cancer Research Workshop
- 2015 Conquer Cancer Foundation of ASCO Merit Award
- 2014 ASCO Young Investigator Award